Table 1. Patient demographics, disease characteristics, and conditioning regimen.

Characteristics	N (%)
Gender
Male	38 (75)
Female	13 (25)
Age (median years, range)	44 (23 – 74)
Diagnosis
ALL	51 (100)
Ph (+)	15 (29)
Ph (–)	36 (71)
CD19+ CAR T-cell dose
4×105	1 (2)
1×106	19 (37)
3×106	31 (61)
Conditioning regimen prior to CD19+ CAR T-cell therapy
Cyclophosphamide 3,000 mg/m2	27(53)
Cyclophosphamide 1,500 mg/m2	11 (21)
Cyclophosphamide 3,000 mg/m2 + fludarabine 25 mg/m2	8 (16)
Cycloposphamide 60 mg/kg + fludarabine 25 mg/m2	2 (4)
Cyclophosphamide 3,000 mg/m2 + dasatinib 100 mg	2 (4)
Cyclophosphamide 400 mg/m2 + clofarabine 20 mg/m2	1 (2)